
Oncology NEWS International
- Oncology NEWS International Vol 17 No 4
- Volume 17
- Issue 4
Tremelimumab trial discontinued
Pfizer Inc has discontinued a phase III trial of single-agent tremelimumab in patients with advanced melanoma after the review of interim data showed that the trial would not demonstrate superiority to standard chemotherapy.
NEW YORK-Pfizer Inc has discontinued a phase III trial of single-agent tremelimumab in patients with advanced melanoma after the review of interim data showed that the trial would not demonstrate superiority to standard chemotherapy. “We will continue to assess the study data to understand the clinical benefit seen in some patients who received tremelimumab,” said Pfizer’s Charles Baum, MD, PhD.
Articles in this issue
almost 18 years ago
Proton therapy training offeredalmost 18 years ago
Editor of Blood reviews a very bloody moviealmost 18 years ago
Artists take note: Oncology on Canvas accepting entriesalmost 18 years ago
PET affects treatment in over one-third of cancer casesalmost 18 years ago
Expanded use of Axxent approvedalmost 18 years ago
Gardasil supplemental application gets priority review designationalmost 18 years ago
Optical tomo/US monitors adjuvant chemo responsealmost 18 years ago
GIST patients resistant to imatinib/sunitinib respond to sorafenibalmost 18 years ago
Sunitinib plus a taxane active in advanced breast canceralmost 18 years ago
Stanford V yields excellent outcomes in bulky, advanced HLNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



































